Chemomab Therapeutics (CMMB) Expected to Announce Earnings on Wednesday

Chemomab Therapeutics (NASDAQ:CMMB) is expected to issue its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Chemomab Therapeutics to post earnings of ($0.04) per share for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 21, 2026 at 12:30 PM ET.

Chemomab Therapeutics (NASDAQ:CMMB) last issued its earnings results on Thursday, March 19th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). On average, analysts expect Chemomab Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Chemomab Therapeutics Price Performance

Shares of CMMB stock opened at $1.77 on Monday. The company has a market cap of $12.73 million, a P/E ratio of -0.69 and a beta of 0.51. The business has a 50 day moving average of $1.71 and a two-hundred day moving average of $1.99. Chemomab Therapeutics has a 52 week low of $1.35 and a 52 week high of $5.88.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Chemomab Therapeutics stock. ADAR1 Capital Management LLC bought a new position in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 80,000 shares of the company’s stock, valued at approximately $132,000. ADAR1 Capital Management LLC owned about 1.30% of Chemomab Therapeutics at the end of the most recent quarter. 46.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Chemomab Therapeutics in a report on Friday. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $25.00.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.